EYE 2.22% 23.0¢ nova eye medical limited

POTENTIAL RE-RATE CATALYST EVENT: RESULTS, page-111

  1. 111 Posts.
    lightbulb Created with Sketch. 102
    Hi Epichemist,

    I really hope your estimates will prove being too cautious. If I peg your US sales estimates for Mar-Jun 2024 into the model, EYE would be a pretty far stretch off showing triple-digit growth numbers for the US in any of these months. Which I guess the market would consider as rather disapointing. And so would I.

    https://hotcopper.com.au/data/attachments/6293/6293980-03aacd9b5d39b5c5661272f98fb944ef.jpg

    I am surprised @TheAnalyst007 and @StealthInvest deem your estimate being „pretty reasonable“ and „a sensible ballpark“.

    US$7-8 M for the US in 2H2024 (the key number to watch) should be needed to see the stock breaking the 28/30ct resistance. Without, I fear EYE would be left another six months without hard numbers that really underpin iTrack Advance‘ success for the broader and the professional investment community.

    Good luck to all of us for next week.

    Last edited by PigRace: 07/07/24
 
watchlist Created with Sketch. Add EYE (ASX) to my watchlist
(20min delay)
Last
23.0¢
Change
0.005(2.22%)
Mkt cap ! $52.68M
Open High Low Value Volume
23.0¢ 24.0¢ 23.0¢ $36.78K 159.5K

Buyers (Bids)

No. Vol. Price($)
2 52300 22.5¢
 

Sellers (Offers)

Price($) Vol. No.
23.0¢ 53718 1
View Market Depth
Last trade - 14.44pm 23/08/2024 (20 minute delay) ?
EYE (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.